Stem cell transplant Patients' vaccine response under the microscope

NCT ID NCT03659773

Completed Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at how well recommended vaccines protect adults who have had a stem cell transplant. Researchers took blood samples from 152 transplant recipients before and after vaccination to measure antibody levels against diseases like tetanus, diphtheria, and hepatitis B. The goal was to understand if the vaccines trigger a strong immune response in these patients, who are at high risk for infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors improve vaccination schedules for stem cell transplant recipients, reducing their risk of serious infections.
What could go wrong: This is an observational study, not a treatment trial. It only measures immune responses and does not test a new vaccine or therapy, so direct patient benefits are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELLS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC STEM CELLS VACCINATION

Contacts and locations

Locations

Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Hôpital de la Croix Rousse

Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.